Contezolid: First Approval

Contezolid 康替唑胺 (Youxitai 优喜泰 ® ), an orally administered oxazolidinone antibacterial agent, is being developed by Shanghai MicuRx Pharmaceutical Co., Ltd. for the treatment of multidrug-resistant (MDR) Gram-positive bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA)...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drugs (New York, N.Y.) N.Y.), 2021-09, Vol.81 (13), p.1587-1591
1. Verfasser:	Hoy, Sheridan M.
Format:	Artikel
Sprache:	eng
Schlagworte:	AdisInsight Report Anti-Bacterial Agents - pharmacokinetics Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Antibacterial agents Antibiotic resistance Antiinfectives and antibacterials Bacterial diseases Bacterial infections China Diabetes Diabetes mellitus Drug Approval Drug dosages Drug Resistance, Multiple, Bacterial Foot diseases Gram-positive bacteria Gram-Positive Bacterial Infections - drug therapy Health services Humans Infections Internal Medicine Medical equipment Medicine Medicine & Public Health Metabolites Methicillin Methicillin-Resistant Staphylococcus aureus Multidrug resistance Multidrug resistant organisms Oral administration Oxazolidinones - pharmacokinetics Oxazolidinones - pharmacology Oxazolidinones - therapeutic use Pharmacokinetics Pharmacology/Toxicology Pharmacotherapy Population Pyridones - pharmacokinetics Pyridones - pharmacology Pyridones - therapeutic use Skin Soft tissues Staphylococcus aureus Staphylococcus infections Streptococcus infections Tuberculosis Vancomycin Vancomycin Resistance
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!